Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip G de Groot

Showing results (21-30 of 224) with videos related to

Pageof 23
Sort By:
Current Opinion in Hematology|July 17, 2004
Antiphospholipid antibodies: update on detection, pathophysiology, and treatmentPhilip G de Groot, Ronald H W M Derksen
Current Opinion in Infectious Diseases|May 3, 2005
The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesisPhilip G de Groot, Ronald H M W Derksen
Nature Clinical Practice. Rheumatology|February 21, 2008
Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanismBas de Laat, Koen Mertens, Philip G de Groot
The New England Journal of Medicine|August 15, 2003
SARS in Hong KongYa Ping Wu, Ran Wei, Philip G de Groot
Handbook of Experimental Pharmacology|August 25, 2012
Platelet interaction with the vessel wallPhilip G de Groot, Rolf T Urbanus, Mark Roest
Journal of Hepatology|July 20, 2002
Haemostatic abnormalities in patients with liver diseaseTon Lisman, Frank W G Leebeek, Philip G de Groot
Blood|July 10, 2008
The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surfaceCees Weeterings, Philip G de Groot, Jelle Adelmeijer, et al.
Seminars in Thrombosis and Hemostasis|September 13, 2017
The Lupus Anticoagulant ParadoxJessica E Molhoek, Philip G de Groot, Rolf T Urbanus
Thrombosis and Haemostasis|October 17, 2007
Suppressing platelet microparticle formation by antibodies against platelet glycoprotein GPIbXiao Min Zhao, Ya Ping Wu, Philip G de Groot
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 10, 2003
Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factorTon Lisman, Jelle Adelmeijer, H Karel Nieuwenhuis, et al.
Pageof 23

Showing results (21-30 of 224) with videos related to

Sort By:
Pageof 23
Current Opinion in Hematology|July 17, 2004
Antiphospholipid antibodies: update on detection, pathophysiology, and treatmentPhilip G de Groot, Ronald H W M Derksen
Current Opinion in Infectious Diseases|May 3, 2005
The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesisPhilip G de Groot, Ronald H M W Derksen
Nature Clinical Practice. Rheumatology|February 21, 2008
Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanismBas de Laat, Koen Mertens, Philip G de Groot
The New England Journal of Medicine|August 15, 2003
SARS in Hong KongYa Ping Wu, Ran Wei, Philip G de Groot
Handbook of Experimental Pharmacology|August 25, 2012
Platelet interaction with the vessel wallPhilip G de Groot, Rolf T Urbanus, Mark Roest
Journal of Hepatology|July 20, 2002
Haemostatic abnormalities in patients with liver diseaseTon Lisman, Frank W G Leebeek, Philip G de Groot
Blood|July 10, 2008
The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surfaceCees Weeterings, Philip G de Groot, Jelle Adelmeijer, et al.
Seminars in Thrombosis and Hemostasis|September 13, 2017
The Lupus Anticoagulant ParadoxJessica E Molhoek, Philip G de Groot, Rolf T Urbanus
Thrombosis and Haemostasis|October 17, 2007
Suppressing platelet microparticle formation by antibodies against platelet glycoprotein GPIbXiao Min Zhao, Ya Ping Wu, Philip G de Groot
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 10, 2003
Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factorTon Lisman, Jelle Adelmeijer, H Karel Nieuwenhuis, et al.
Pageof 23